ID
15393
Description
Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02150317
Link
https://clinicaltrials.gov/show/NCT02150317
Keywords
Versions (1)
- 5/29/16 5/29/16 -
Uploaded on
May 29, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Advanced Hepatocellular Carcinoma NCT02150317
Eligibility Advanced Hepatocellular Carcinoma NCT02150317
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
Study Subject Participation Status
Data type
boolean
Alias
- UMLS CUI [1]
- C0525058
- UMLS CUI [2]
- C0009488
Description
Malignant Neoplasms
Data type
boolean
Alias
- UMLS CUI [1]
- C0006826
Description
subjects participating in other clinical trials
Data type
boolean
Alias
- UMLS CUI [1]
- C2348568
Description
Child-Pugh Class C
Data type
boolean
Alias
- UMLS CUI [1]
- C3831115
Description
no pathological evidence of hepatocellular carcinoma.
Data type
boolean
Alias
- UMLS CUI [1]
- C0205469
Similar models
Eligibility Advanced Hepatocellular Carcinoma NCT02150317
- StudyEvent: Eligibility
C0474915 (UMLS CUI [2])
C0428441 (UMLS CUI [2])
C0009488 (UMLS CUI [2])